Breast Cancer Research Program

项目摘要 艾布拉姆森癌症中心（ACC）的乳腺癌项目于1994年正式成立， 自1999年以来一直获得NCI的批准。该计划目前由Angela DeMichele，MD领导， MSCE是临床试验和转化生物标志物研究方面的专家， 2005年，和罗杰格林伯格，医学博士，博士，谁在乳腺癌生物学的互补背景， （侧重于BRCA依赖的DNA修复）和遗传易感性。格林伯格博士最近取代了。 Chodosh，ACC的基础研究广告，谁继续是一个积极的成员。项目成员 关注乳腺癌的根本原因，以提高检测、预防和 治疗这种疾病。他们共同努力，通过专注于四个关键科学领域来实现这一目标：1） 阐明乳腺癌发生和发展的遗传和分子机制; 2） 改进遗传风险评估和开发新的预防策略; 3）开发 创新的成像方法，以改善乳腺癌的检测和评估的治疗 4）将实验室发现转化为新的治疗方法和反应生物标志物， 结果。成员之间的互动性很强，这反映在他们领导了多项合作赠款， 包括NCI U 01，NCI U 54，国防部（DOD）乳腺癌卓越中心， 美国国防部创意奖，Basser乳腺癌中心，2-PREVENT乳腺癌转化中心， 卓越和众多跨学科转化临床试验。除了促进内部和内部- 项目合作，项目领导强调乳腺癌转化研究是一个 主要重点，实施乳腺癌生物标本库和数据库，招聘外部教师， 为该计划提供重要的新专业知识，并举办或参加ACC的主要务虚会， 乳腺癌研究。ACC对临床研究的投资，特别是跨学科的雷纳 罗文乳腺中心，促进了以病人为导向的研究。该计划由19名成员组成， 佩雷尔曼医学院和艺术与科学学院的八个部门。这些成员 拥有900万美元的癌症相关赠款资金（年度直接成本），其中750万美元用于同行评审，460万美元用于 国家癌症研究所资助在本项目期间，成员发表了316篇与癌症有关的论文，其中9% 是项目内合作的结果，51%是项目间合作的结果， 34%是多机构的。

Project Summary The Breast Cancer Program of the Abramson Cancer Center (ACC) was formally established in 1994 and has been continuously approved by the NCI since 1999. The Program is currently led by Angela DeMichele, MD, MSCE, an expert in clinical trials and translational biomarker research who has served as a Co-Leader since 2005, and Roger Greenberg, MD, PhD, who has a complementary background in breast cancer biology (focusing on BRCA-dependent DNA repair) and genetic susceptibility. Dr. Greenberg recently replaced Dr. Chodosh, the ACC's AD for Basic Research, who continues to be an active member. Members of the Program are focused on understanding the underlying causes of breast cancer to improve the detection, prevention, and treatment of this disease. They work together to achieve this goal by focusing on four key scientific areas: 1) Elucidation of the genetic and molecular mechanisms of breast cancer development and progression; 2) Improvements in genetic risk assessment and development of novel prevention strategies; 3) Development of innovative imaging approaches to improve breast cancer detection and the assessment of therapeutic response; and 4) Translation of laboratory discoveries to novel therapeutics and biomarkers of response and outcome. Members are highly interactive, as reflected in their leadership of multiple collaborative grants, including an NCI U01, an NCI U54, a Department of Defense (DOD) Breast Cancer Center of Excellence, a DOD Idea Award, the Basser Center for BRCA, the 2-PREVENT Breast Cancer Translational Center of Excellence and numerous interdisciplinary translational clinical trials. In addition to facilitating intra- and inter- Programmatic collaborations, Program Leadership has emphasized breast cancer translational research as a major focus, implementing a breast cancer biospecimen bank and database, recruiting external faculty with important new expertise to the Program, and holding or participating in major ACC retreats that emphasize breast cancer research. The ACC's investment in clinical research, particularly the interdisciplinary Rena Rowan Breast Center, has facilitated patient-oriented research. The Program consists of 19 members from eight departments in the Perelman School of Medicine and the School of Arts and Sciences. These members have $9M in cancer-related grant funding (annual direct costs), of which $7.5M is peer-reviewed and $4.6M is NCI-funded. During the current project period, members published 316 cancer-related papers, of which 9% were the result of intra-Programmatic collaborations, 51% were the result of inter-Programmatic collaborations, and 34% were multi-institutional.